Glytec Chief Medical Officer Named to Becker's Hospital Review's 2025 List of "Patient Safety Experts to Know"

BOSTON, Aug. 28, 2025 /PRNewswire/ -- Glytec, the leading provider of an AI-powered technology platform for diabetes and related conditions for hospitals and health systems, today announced that its Chief Medical Officer, Jordan Messler, MD, SFHM, FACP, has been named by Becker's Hospital Review as one of its 2025 "Patient Safety Experts to Know."

The annual list recognizes 132 leaders nationwide who are advancing patient safety and strengthening the quality of care within their organizations. According to Becker's, honorees are instrumental in reducing hospital-acquired infections, preventing adverse events, and ensuring strict regulatory compliance—all while helping providers safeguard patients from preventable errors and risks ranging from day-to-day complications to large-scale disasters.

Dr. Messler has long been a champion for patient safety in diabetes and glycemic management, with a strong focus on advancing technology that meets the rigorous FDA safety and effectiveness standards. At Glytec, he has led nationwide efforts to help hospitals and health systems implement Glucommander^®, the company's FDA-cleared, EHR-integrated insulin dosing software. The solution reduces the risks of hyperglycemia and hypoglycemia, two conditions at the center of new CMS reporting measures beginning in January 2026.

Under his leadership, Glytec has shown that Glucommander^® delivers meaningful results: fewer hypoglycemic events, shorter hospital stays, reduced readmissions, and an average 6–8x return on investment. Drawing on his hospital experience, Dr. Messler has made Glytec's solutions turn-key for clients. They integrate easily with IT systems, automate clinician workflows, and provide powerful analytics to measure patient-days in target range, time to glucose control, avoided adverse events and costs, financial outcomes, and CMS eCQM readiness.

"Patient safety is at the heart of everything we do at Glytec," said Patrick Cua, CEO of Glytec. "It's an honor for Dr. Messler to be recognized by Becker's alongside so many distinguished leaders who share this mission. This recognition reflects Glytec's commitment to equipping providers with the tools they need to deliver safer, higher-quality, innovative care to every patient, every time."

This recognition follows a series of honors for Glytec in 2025, including being named winner of the Gold Stevie^® Award as the Healthcare Technology Company of the Year in the second annual Stevie Awards for Technology Excellence

About Glytec

Glytec's industry-leading, AI-driven technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay and readmissions, and optimizing clinical workflows. Its flagship solution, Glucommander^®—the first-ever FDA-cleared cloud-based insulin management software, integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and comprehensive analytics. Supported by industry awards and over 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from the hospital to the home for consumers, providers, and payors. For more information, visit www.glytec.com or follow Glytec on LinkedIn.

Media Contact:
Glytec Public Relations
[email protected] 

SOURCE Glytec, LLC